Tender Offer | ₹81.00 Crores | Listed at BSE, NSE | Wed, Dec 31, 2025 - Tue, Jan 6, 2026
Nectar Lifesciences Ltd. Buyback is a tender offer for the repurchase of up to 3.00 crore equity shares, representing 13.38% of the total paid-up equity share capital at a buyback price of ₹27 per share with a face value of ₹1 per share, aggregating to ₹81.00 crores.
The record date for determining eligible shareholders is Dec 24, 2025. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on Dec 31, 2025 and closes on Jan 6, 2026, with the last date for receipt of tender forms being Jan 6, 2026.
The finalisation of buyback acceptance is expected on Jan 12, 2026, followed by settlement of bids on Jan 13, 2026.
Master Capital Services Ltd. is the Manager to the Buyback and Kfin Technologies Ltd. is the Registrar and Master Capital Service Limited is the Registered Broker to the Buyback.
Investors are advised to refer to the Nectar Lifesciences Ltd. Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Wed, Dec 31, 2025
Offer Closing Date
Tue, Jan 6, 2026
Buyback Price
₹27 per share
Record Date
December 24, 2025
| Category | Entitlement Ratio of Buyback | Shares Offered |
|---|---|---|
| Reserved Category for Small Shareholders | 25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date. | 1,32,51,651 |
| General Category for all other Eligible Shareholders | 25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date. | 1,67,48,349 |
Nectar Lifesciences Ltd.'s revenue decreased by 1% and profit after tax (PAT) dropped by 2376% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Total Income | 11.30 | 1,674.97 | 1,698.66 | 1,566.85 |
| Profit After Tax | -1.01 | -113.68 | 4.99 | -24.18 |
| NET Worth | 716.87 | 956.11 | 1,069.25 | 1,064.59 |
| Reserves and Surplus | 694.44 | 933.68 | 1,046.82 | 1,042.17 |
| Total Borrowing | 458.85 | 582.02 | 635.54 | 753.83 |
| Amount in ₹ Crore | ||||
Nectar Lifesciences is a research-driven, fully integrated pharmaceutical company. Its core business revolves around manufacturing Active Pharmaceutical Ingredients (APIs) — especially cephalosporin antibiotics — as well as intermediates.
Beyond APIs, the company also produces finished dosage forms (FDFs / formulations) — such as tablets, capsules, suspensions, granules, and injectables — through contract manufacturing. They also manufacture empty hard gelatin capsules (EHGCs) and have a presence in phytochemicals / menthol-based products.
Nectar has multiple state-of-the-art manufacturing facilities: 13 facilities across Punjab and Himachal Pradesh (oral and sterile drug production, empty capsule production, menthol/phytochemicals).
The plants are compliant with global regulatory standards (cGMP / EHS) and have approvals from international regulatory authorities (for export markets) — underscoring their quality assurance.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Nov-2025 | 16.99 | 13.75 | 14.67 |
| Oct-2025 | 16.01 | 13.31 | 14.26 |
| Sep-2025 | 17.03 | 14.07 | 15.15 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Nov-2025 | 16.99 | 13.71 | 14.64 |
| Oct-2025 | 15.76 | 13.10 | 14.18 |
| Sep-2025 | 16.99 | 14.03 | 15.12 |
Nectar Lifesciences Ltd.
Shop No. 5, SL Enclave,
Behind Sohi HP Gas Agency,
Barwala Road,
Dera Bassi, Punjab, 140507
Lead Manager(s)
Registered Broker
The Nectar Lifesciences Buyback 2025 opens on December 31, 2025, and closes on January 6, 2026.
Last date to be eligible to participate in buyback is December 23, 2025.
The Nectar Lifesciences Buyback 2025 is a Tender Offer.
Nectar Lifesciences Buyback 2025 Schedule
| Buyback Opening Date | December 31, 2025 |
| Buyback Closing Date | January 6, 2026 |
| Last Date for receipt of Tender Forms | January 6, 2026 |
| Finalisation of Buyback Acceptance | January 12, 2026 |
| Last Date for settlment of bids | January 13, 2026 |
| Last Date for Extinguishment of Shares | January 22, 2026 |
The Nectar Lifesciences Buyback 2025 is being offered at Rs ₹27 per share.
| Category | Entitlement Ratio of Buyback | Shares Offered |
|---|---|---|
| Reserved Category for Small Shareholders | 25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date. | 1,32,51,651 |
| General Category for all other Eligible Shareholders | 25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date. | 1,67,48,349 |
The issue size of Nectar Lifesciences Buyback 2025 is 3,00,00,000 equity shares at ₹27 per share aggregating up to ₹81.00 Crores.
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Nectar Lifesciences Buyback 2025 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
